Ixazomib, as an oral proteasome inhibitor, has received attention from patients regarding its marketing status in China. Whether long-term use is necessary depends on the type of disease, treatment stage, and individual patient response. The following will provide a detailed introduction.

1. Domestic listing status

(1) According to the drug approval records, Isazomib has been approved for marketing by the China National Medical Products Administration.

(2) This drug is an imported original research drug, and currently there is no information on the approval of generic drugs in China.

Scope of indications 2

(1) Approved for combination therapy of multiple myeloma, it needs to be used in combination with lenalidomide and dexamethasone.

(2) Suitable for the population of recurrent or refractory patients who have received at least first-line treatment.

3 Medication precautions

(1) It should be used under the guidance of a hematology specialist, and a complete blood cell count test should be performed before treatment.

(2) Common adverse reactions include thrombocytopenia, diarrhea, and peripheral neuropathy, which require regular monitoring.

4 Special Population Restrictions

(1) Patients with moderate to severe liver function impairment need to adjust the dosage to 3mg once a week.

(2) Prohibited during pregnancy, women of childbearing age should take effective contraceptive measures.

5 standard treatment cycles

(1) Combination therapy: When used in combination with lenalidomide/dexamethasone, every 28 days is considered as one cycle, with daily oral intake for the first 3 weeks and discontinuation in the 4th week.

(2) Maintenance therapy: For patients who have achieved remission, it can be used for a long time until disease progression or intolerable toxicity occurs.

6 Criteria for Drug Discontinuation Determination

(1) Disease progression: When it is confirmed that imaging or laboratory indicators have deteriorated, treatment should be terminated and the plan changed.

(2) Serious toxicity: Patients with grade 4 hematological toxicity or grade 3 or above non hematological toxicity who relapse after dose adjustment.